来自MSN1 个月
FDA lifts clinical hold on Amylyx’s Phase I ALS trial
The US Food and Drug Administration (FDA) has lifted a clinical hold on Amylyx Pharmaceuticals’ Phase I trial of AMX0114 in amyotrophic lateral sclerosis (ALS). The lift allows Amylyx to open US ...
来自MSN1 个月
FDA clears Amylyx to resume ALS drug trial in North America
It aims to evaluate the safety and biological activity of AMX0114, which targets calpain-2, a protein linked to neurodegenerative processes. Approximately 48 individuals with ALS will be involved ...